1 results match your criteria: "Stanford University School of Medicine HRP Redwood Building[Affiliation]"
Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer.
J Comp Eff Res
October 2019
Departments of Medicine (Oncology) & of Health Research & Policy, Women's Clinical Cancer Genetics Program, Stanford University School of Medicine HRP Redwood Building, Room T254A, 150 Governor's Lane, Stanford, CA 94305, USA.
This observational study evaluated the effectiveness of nab-paclitaxel versus paclitaxel monotherapy as first-line (1L) treatment for metastatic triple-negative breast cancer (mTNBC). 200 patients from the US Flatiron Health electronic health record-derived database (mTNBC diagnosis, January 2011-October 2016) who received 1L nab-paclitaxel (n = 105) or paclitaxel (n = 95) monotherapy were included. Overall survival and time to next treatment were evaluated.
View Article and Find Full Text PDF